Polynoma is an immuno-oncology company developing seviprotimut-L, a novel polyvalent shed antigens vaccine for the adjuvant treatment of melanoma.
Polynoma LLC is headquartered in San Diego, California and is a wholly-owned subsidiary of CK Life Sciences Int’l., (Holdings) Inc. For further information about Polynoma, please contact email@example.com, and for information about CK Life Sciences Int’l. visit www.ck-lifesciences.com.
Chief Executive Officer
Patrick Mallon is Chief Executive Officer of Polynoma LLC (“Polynoma”) and is responsible for the management of preclinical, clinical development and operations, regulatory affairs, CMC/manufacturing, commercial development and quality functions of the Company. Mr. Mallon joined Polynoma in 2012. He holds a Bachelor’s degree in Medical Technology, and has extensive senior and C-level executive experience… Read More
Chief Financial Officer
Andrew Buckland is Polynoma’s Chief Financial Officer and is responsible for financial operations. Mr. Buckland joined Polynoma in 2012. He earned an MBA from the University of California, Irvine and holds a BA (with Honors) from the University of the West of England. Mr. Buckland has extensive experience in the development of financial operations within both large multinational… Read More
Chief Technology Officer
Melvin Toh is Chief Technology Officer responsible for technology and clinical research and development activities of Polynoma. He is also the Vice President and Chief Scientific Officer of CK Life Sciences Int’l., (Holdings) Inc., Polynoma’s parent company. He holds Bachelor of Medicine and Bachelor of Surgery degrees from the National University of Singapore and a Master of Science degree in Epidemiology… Read More
Alan Yu is Polynoma’s Chairman and is the Vice President and Chief Executive Officer of CK Life Sciences (“CKLS”). Prior to becoming CKLS Vice President and Chief Executive Officer, Mr. Yu had been Vice President and Chief Operating Officer of CKLS since June 2002, and has been a member of the CKLS Nomination Committee since January 2019…Read More